Intra-operatively placed cryopreserved placental tissue allograft (CPTA) has shown promise in expediting the recovery urinary continence (UC) following robot-assisted radical prostatectomy (RARP). In this retrospective review of a prospectively maintained single-surgeon, single-institution RARP database, we compare three groups of patients: historical controls (C; N  = 183 men) that received no allograft versus two different CPTA products (total CPTA N  = 162 A1 N  = 81; A2 N  = 81). The CPTA product was intra-operatively placed as an onlay over the area of the neurovascular bundles during RARP. CPTA cases had significantly faster median time to UC (A1 = 1.4 months; A2 = 1.45 months) versus controls (1.64 months), p  = 0.01. On multivariable analysis, use of A1 (HR 1.55, 95% CI 1.14–2.09, p  = 0.005) and use of A2 (HR 1.53, CI 1.11–2.11, p  = 0.01) were significantly associated with quicker return of UC. Older age (HR 0.97, CI 0.96–0.99, p  = 0.001) and non-organ-confined clinical stage (HR 0.51, CI 0.26–1.0 p  = 0.05), were significantly associated with slower return of UC. In a propensity score-matched analysis of 77 CPTA patients with sufficient follow-up versus controls, there was significantly less biochemical recurrence (BCR; p  = 0.01). Our study indicates that CPTA use appears to accelerate time to UC in age- and performance status-matched men undergoing RARP without increased risk of BCR.